Heavy Menstrual Bleeding: Modern Treatment Strategies in Women of Reproductive Age
DOI:
https://doi.org/10.37800/RM.3.2025.501Keywords:
Heavy menstrual bleeding (HMB), quality of life, combined oral contraceptive containing dienogest and estradiol, evonorgestrel-releasing intrauterine system (LNG-IUS), tranexamic acid, reproductive ageAbstract
Relevance:Heavy menstrual bleeding (HMB) is a common gynecological problem among women of reproductive age, significantly affecting their quality of life.
The study aimed to determine the optimal conservative method of treating heavy menstrual bleeding in women of reproductive age based on an analysis of clinical efficacy, safety, and impact on patients’ quality of life in real clinical practice.
Materials and Methods: The study included two stages: a survey of 180 women, 33.3% of whom were diagnosed with HMB, and an evaluation of treatment outcomes using three methods: the combined oral contraceptive (COC) containing dienogest and estradiol, the levonorgestrel-releasing intrauterine system, and tranexamic acid.
Results: All treatments under study demonstrated positive clinical effect, but the greatest clinical efficacy was demonstrated by the COC containing dienogest and estradiol, which provided a more pronounced reduction in blood loss, stabilization of hemoglobin levels, and a positive effect on subjective indicators of quality of life. Differences in patient tolerability and satisfaction were also found between treatment methods.
Conclusion: The study highlights the feasibility of using a COC containing dienogest and estradiol as a first-line treatment for HMB in women of reproductive age.
References
1. Ibrahim PM, Samwel EL. Prevalence of Heavy Menstrual Bleeding and Its Associated Factors Among Women Attending Kilimanjaro Christian Medical Centre In Northern Eastern, Tanzania: A Cross-Sectional Study. East Afr Health Res J. 2023;7(1):1-6.
https://doi.org/10.24248/eahrj.v7i1.702
2. Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia A. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet. 2015;128(3):196-200.
https://doi.org/10.1016/j.ijgo.2014.09.027
3. Шегенов Г., Искаков С., Мукышбекова М., Марат А. Качество жизни женщин репродуктивного возраста с обильными маточными кровотечениями. Репродуктивная медицина (Центральная Азия). 2024;2:54-59.
Shegenov G, Iskakov S, Mukyshbekova М, Marat А. Heavy menstrual bleeding and quality of life in women of reproductive age. Reproductive Medicine (Central Asia). 2024;2:54-59. Russian.
https://doi.org/10.37800/RM.2.2024.54-59
4. WHO. Anaemia in women and children [Internet]. World Health Organization. 2021 [cited 2025 May 14]. Available from:
https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children
5. NICE. Overview | Heavy menstrual bleeding: assessment and management | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2018 [cited 2025 May 14]. Available from:
https://www.nice.org.uk/guidance/ng88
6. Lim MY, Olson L, Rajpurkar MA, Weyand AC. Concomitant use of combined hormonal contraceptives and antifibrinolytic agents for the management of heavy menstrual bleeding: A practice pattern survey. Thrombosis Res. 2021;204:95-100.
https://doi.org/10.1016/j.thromres.2021.06.006
7. Калинкина О.Б. Эффективность внутриматочного контрацептива, содержащего левоноргестрел (мирены) при терапии обильных менструальных кровотечений. Медико-фармацевтический журнал «Пульс». 2021;23(7):80-85.
Kalinkina OB. Effectiveness of an intrauterine contraceptive containing levonorgestrel (mirena) in the treatment of heavy menstrual bleeding. Medical & pharmaceutical journal "Pulse". 2021;23(7):80-85. Russian.
8. Андреева Е.Н., Хамошина М.Б., Цапиева Е.О. Медикаментозная терапия обильных менструаций: вчера и сегодня. Доктор.Ру. 2013;7-1(85):33-37.
Andreeva EN, Khamoshina MB, Tsapieva EO. Medication Treatment for Heavy Menstrual Bleeding: Yesterday and Today. Doctor.Ru. 2013;7-1(85):33-37. Russian.
https://cyberleninka.ru/article/n/medikamentoznaya-terapiya-obilnyh-menstruatsiy-vchera-i-segodnya
9. Чернуха Г.Е. Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения. Гинекология. 2024;26(3):260-269.
Chernukha GE. Heavy menstrual bleeding and anemia: The problem is growing and requires a solution. A review. Gynecology. 2024;26(3):260–269. Russian.
https://doi.org/10.26442/20795696.2024.3.202894
10. Sriprasert I, Pakrashi T, Kimble T, Archer DF. Heavy menstrual bleeding diagnosis and medical management. Contracept Reprod Med. 2017;2:20.
https://doi.org/10.1186/s40834-017-0047-4
11. Kocaoz S, Cirpan R, Degirmencioglu AZ. The prevalence and impacts heavy menstrual bleeding on anemia, fatigue and quality of life in women of reproductive age. Pakistan J Med Sci. 2019;35(2):365-370.
https://doi.org/10.12669/pjms.35.2.644
12. Bryant‐Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2018;4:CD000249.
https://doi.org/10.1002/14651858.cd000249.pub2
13. Mansour D, Hofmann A, Gemzell-Danielsson K. A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding. Adv Ther. 2021 Jan;38(1):201-225.
https://doi.org/10.1007/s12325-020-01564-y
14. Jensen JT, Bitzer J, Nappi RE, Ahlers C, Bannemerschult R, Parke S. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur J Contracept Reprod Health Care. 2020 Apr;25(2):98-105.
https://doi.org/10.1080/13625187.2020.1731734
15. Chen S, Liu J, Peng S, Zheng Y. LNG-IUS vs. medical treatments for women with heavy menstrual bleeding: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:948709.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 К.Ж. Халмуратова , Р.Н. Космуратова, А.А. Есжанова , С.К. Куаныш , Г.А. Сагандыкова , Ш.Б. Космуратова
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
